Elan announces launch of extended release Ampyra in U.S.

Following its approval earlier this year, Elan Drug Technologies has announced the launch of Ampyra (dalfampridine) by Acorda Therapeutics in the U.S. as a treatment to improve walking in patients with multiple sclerosis. The first NDA approved and launched incorporating Elan's MXDAS technology, Ampryra was developed using a hydrophilic matrix, which controls the rate of release of dalfampridine through a process of diffusion and erosion in the gastrointestinal tract. Release

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.